LOLLO Giovanna

LOLLO Giovanna

Fonction : Maitre de conférence

Equipe : GEPHARM

Competence :

Design and development of novel drug delivery nanosystems to overcome physiological barriers for the treatment of various diseases.

Bureau : G119

Téléphone : 04 72 44 85 84

e-mail : M’envoyer un message

Spécialité :

Génie Pharmaceutique</

6 documents

  • Flavia Carton, Mathieu Repellin, Giovanna Lollo, Manuela Malatesta. Alcian blue staining to track the intracellular fate of hyaluronic-acid-based nanoparticles at transmission electron microscopy.. European journal of histochemistry : EJH, 2019. ⟨hal-02415884⟩
  • Laura Pinton, Elena Masetto, Marina Vettore, Samantha Solito, Sara Magri, et al.. The immune suppressive microenvironment of human gliomas depends on the accumulation of bone marrow-derived macrophages in the center of the lesion. Journal for Immunotherapy of Cancer, London : BioMed Central, 2013-, 2019, 7 (1). ⟨hal-02055603⟩
  • Giovanna Lollo, Kevin Matha, Martina Bocchiardo, Jérôme Bejaud, Ilaria Marigo, et al.. Drug delivery to tumours using a novel 5-FU derivative encapsulated into lipid nanocapsules. Journal of Drug Targeting, Informa Healthcare, 2018, pp.1-12. ⟨10.1080/1061186X.2018.1547733⟩. ⟨hal-02055594⟩
  • Giovanna Lollo, Gabriela Ullio-Gamboa, Edmundo Fuentes, Kevin Matha, Nolwenn Lautram, et al.. In vitro anti-cancer activity and pharmacokinetic evaluation of curcumin-loaded lipid nanocapsules. Materials Science and Engineering: C, Elsevier, 2018, 91, pp.859-867. ⟨hal-02055602⟩
  • Maria Sasso, Giovanna Lollo, Marion Pitorre, Samantha Solito, Laura Pinton, et al.. Low dose gemcitabine-loaded lipid nanocapsules target monocytic myeloid-derived suppressor cells and potentiate cancer immunotherapy. Biomaterials, Elsevier, 2016, 96, pp.47-62. ⟨10.1016/j.biomaterials.2016.04.010⟩. ⟨hal-01392469⟩
  • Giovanna Lollo, Marie Vincent, Gabriela Veroniva Ullio Gamboa, Laurent Lemaire, Florence Franconi, et al.. Development of multifunctional lipid nanocapsules for the co-delivery of paclitaxel and CpG-ODN in the treatment of glioblastoma. International Journal of Pharmaceutics, Elsevier, 2015, 495, pp.972-980. ⟨10.1016/j.ijpharm.2015.09.062⟩. ⟨hal-01392247⟩